medigraphic.com
Colegio de Medicina Interna de México.

2022, Number 2

<< Back Next >>

Med Int Mex 2022; 38 (2)

Epidemiology of chronic kidney disease in Tula de Allende-Tepeji del Río, Hidalgo, México

Polanco-Flores NA

Language: Spanish
References: 19
Page: 248-257
PDF size: 503.88 Kb.


ABSTRACT

Objective: To know the prevalence and epidemiology of chronic kidney disease in the southern area of Hidalgo, Mexico.
Materials and Methods: An observational, descriptive, cross-sectional study of renal function was carried out in patients belonging to the southern area of Hidalgo, Mexico, from January to December 2019.
Resultados: Out of 704 participants, 220 with chronic kidney disease were selected (a prevalence of chronic kidney disease of 31% was determined), from which 20 were eliminated because they didn’t complete satisfactorily the second assessment; so, the study population was of 200 patients. The average serum creatinine value was 4.0 ± 4.7 mg/dL, with a glomerular filtration rate by MDRD of 39 ± 29.4 mL/min/m2, an albuminuria of 1291 ± 346 mg/24 hours. Patients were classified according to KDOQI (Kidney Disease Outcomes Quality Initiative) in stages 1 (6%), 2 (15.5%), 3 (33.5%), 4 (21.5%) and 5 (23.5%). Diabetes mellitus was found in 54%, systemic hypertension in 66.5%; 25% of patients without traditional cause and findings compatible with chronic tubulointerstitial nephritis stood out.
Conclusiones: There is a high percentage of patients with chronic kidney disease of unidentified cause and without known pathogenic risk factors, but with findings compatible with chronic tubulointerstitial nephropathy, which leads us to suspect a probable environmental etiology in the area due to contamination.


REFERENCES

  1. Obrador G, Schultheiss U, Kretzler M, Langham R, Nangaku M, Pecoits-Filho R, et al. Genetic and environmental risk factors for chronic kidney disease. Kidney Int Suppl 2017; 7 (2): 88-106. doi: 10.1016/j.kisu.2017.07.004.

  2. Aminu B, Bisher K, Mohsen E, Meguid E. Epidemiology and pathophysiology of chronic kidney disease. In: Floege J, Johnson R, Feehally J, editors. Comprehensive clinical nephrology. 4th ed. St. Louis Missouri: Elsevier Saunders, 2010; 75 (907-918).

  3. Hsu R, Powe N. Recent trends in the prevalence of chronic kidney disease: Not the same old song. Curr Opin Nephrol Hypertens 2017; 26 (3): 187-196. doi: 10.1097/ MNH.0000000000000315.

  4. Hsu C. Epidemiology of kidney disease. In: Taal MW, Chertow GM, Marsden PA, Skorecki K, Yu ASL, Brenner BM. Brenner & Rector’s The Kidney. 9th ed. Philadelphia: Elsevier Saunders, 2012; 19: 728-739.

  5. Taal MW. Risk factors and chronic kidney disease. In: Taal MW, Chertow GM, Marsden PA, Skorecki K, Yu ASL, Brenner BM. Brenner & Rector’s The Kidney. 9th ed. Philadelphia: Elsevier Saunders, 2012; 21: 758-776.

  6. Meguid E, Bello A. Chronic kidney disease: The global challenge. Lancet 2005; 365: 331-340. doi: 10.1016/S0140- 6736(05)17789-7.

  7. Taal M, Brenner B. Predicting initiation and progression of chronic kidney disease: Developing renal risk scores. Kidney Int 2006; 70 (10): 1694-705. doi: 10.1038/sj.ki.5001794.

  8. Isnard B, Deray G, Baumelou A, Le Quintrec M, Vanherweghem J. Herbs and the kidney. Am J Kidney Dis. 2004; 44 (1): 1-11. doi: 10.1053/j.ajkd.2004.02.009.

  9. Jha V, Rathi M. Natural medicines causing acute kidney injury. Semin Nephrol 2008; 28 (4): 416-28. doi: 10.1016/j. semnephrol.2008.04.010.

  10. Agarwal A, Haddad N, Hebert LA. Progression of kidney disease: Diagnosis and management. In: Molony D, Craig J, eds. Evidence-Based Nephrology. Hoboken, NJ: Wiley; 2008: 311-322.

  11. Muntner P, He J, Vupputuri S, Coresh J, et al. Blood lead and chronic kidney disease in the general United States population: Results from NHANES III. Kidney Int 2003; 63: 1044-1050. doi: 10.1046/j.1523-1755.2003.00812.x.

  12. Yu CC, Lin JL, Lin-Tan DT. Environmental exposure to lead and progression of chronic renal diseases: A four-year prospective longitudinal study. J Am Soc Nephrol 2004; 15: 1016-1022. doi: 10.1097/01.asn. 0000118529.01681.4f.

  13. Roncal C, Mu W, Reunqjui S, Kim KM, et al. Lead, at low levels, accelerates arteriolopathy and tubulointerstitial injury in chronic kidney disease. Am J Physiol Renal Phsyiol. 2007; 293: F1391-F1396. doi: 10.1152/ajprenal.00216.2007.

  14. Ekong E, Jaar B, Weaver V. Lead-related nephrotoxicity: a review of the epidemiologic evidence. Kidney Int 2006; 70: 2074-2084. doi: 10.1038/sj.ki.5001809.

  15. Nangaku M, Fujita T. Chronic interstitial nephritis. In: Floege J, Johnson R, Feehally J. Comprehensive clinical nephrology. 4th ed. St. Louis, Missouri: Elsevier Saunders, 2010; 62: 748-760.

  16. Robles-Osorio M, Sabath-Silva E, Sabath E. Arsenicmediated nephrotoxicity. Ren Fail 2015; 37 (4): 542-7. doi: 10.3109/0886022X.2015.1013419.

  17. Tsai T, Kuo C, Pan W, Chung Y, Chen C, Wu T, et al. The decline in kidney function with chromium exposure is exacerbated with co-exposure to lead and cadmium. Kidney Int 2017; 92 (3): 710-720. https://doi.org/10.1016/j. kint.2017.03.013.

  18. Chávez-Gómez N, Cabello-López A, Gopar-Nieto R, Aguilar- Madrid G, Marin-López K, Aceves-Valdez M, et al. Chronic kidney disease in Mexico and its relation with heavy metals. Rev Med Inst Mex Seguro Soc 2017; 55 (6): 725-734.

  19. Instituto Nacional de Ecología y Cambio Climático (INECC). Informe Nacional de Calidad del Aire 2016, México. Coordinación General de Contaminación y Salud Ambiental, Dirección de Investigación sobre la Calidad del Aire y los Contaminantes Climáticos. Ciudad de México. Diciembre 2017. Consultado en fecha 15/05/2020 y descargado de la página: https://www.gob.mx/inecc/es/articulos/estadode- la-calidad-del-aire-en-mexico?idiom=es




2020     |     www.medigraphic.com